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Nanomaterials are advancing in several directions with significant progress being achieved with respect to their synthesis, func-
tionalization and biomedical application. In this review, we will describe several classes of prototypical nanocarriers, such as lip-
osomes, silicon particles, and gold nanoshells, in terms of their individual function as well as their synergistic use. Active and 
passive targeting, photothermal ablation, and drug controlled release constitute some of the crucial functions identified to achieve 
a medical purpose. Current limitations in targeting, slow clearance, and systemic as well as local toxicity are addressed in refer-
ence to the recent studies that attempted to comprehend and solve these issues. The demand for a more sophisticated understand-
ing of the impact of nanomaterials on the body and of their potential immune response underlies this discussion. Combined com-
ponents are then discussed in the setting of multifunctional nanocarriers, a class of drug delivery systems we envisioned, proposed, 
and evolved in the last 5 years. In particular, our third generation of nanocarriers, the multistage vectors, usher in the new field of 
nanomedicine by combining several components onto multifunctional nanocarriers characterized by emerging properties and able 
to achieve synergistic effects.  
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Nanotechnology has generated significant enthusiasm in the 
research setting due to the superior properties materials gain 
when manufactured at the nanoscale. Current pharmaceuti-
cals fail to operate optimally due to physical and chemicals 
limitations in areas such as delivery, biodistribution and 
pharmacokinetics. Nano-based pharmaceuticals, or “nano-
medicines”, are engineered to either function as a drug or 
carry a drug while addressing these scientific challenges due 
to their nano-size. The nanoscale refers to the relative met-
ric size, with one nanometer being equal to one billionth of 
a meter (roughly the diameter of one molecule of glucose). 
Nanoparticles (NP) are synthesized from a vast number of 
raw materials commonly seen on the macroscale, such as 
gold, lipids, carbon, silica, silicon, and iron [1]. NP made 
from these raw materials exhibited unprecedented properties 
not previously seen at the macroscale. Upon this discovery, 
investigators began exploiting these emerging properties for 
a variety of applications. The tasks performed by these na-
noparticles vary from simple drug protection, as seen in 
siRNA carriers, to magnetic NP that heat up in the presence 
of alternating magnetic fields [2]. This review is an attempt 
to summarize the development of multifunctional nanocar-
riers from their constitutive parts, discuss some of the ex-
isting nanocarriers, and outline the major limitations in the 
production of these advanced technologies. 
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1  Functional nanocomponents 
Multifunctional nanocarriers can be defined as nanoscale 
particles capable of performing at least an additional func-
tion to that of carrying a therapeutic or imaging payload. 
There are several prototypical NP worth describing, as they 
are often the building blocks for larger multifunctional sys-
tems [1]. Amongst organic NP, lipid-based NP such as lip-
osomes and micelles, to date, have achieved the most sig-
nificant clinical success of all NP. Liposomes are 50–300 
nm hollow spheres that mimic the composition of the cellu-
lar bilayer. They are capable of carrying hydrophilic pay-
loads in their interior, as well as trapping hydrophobic drugs 
within their lipid membranes. On the contrary, micelles 
consist of a 10–100 nm spherical monolayer of lipids effec-
tively creating a hydrophobic interior; this allows for the 
transport of hydrophobic drugs within the micelle’s core. 
Multiple chemotherapeutics have been incorporated in these 
lipid based NP, some reaching clinical use in humans. The 
cytotoxic drug doxorubicin has been carried in different NP 
to represent some of the first clinically used nanomedicines. 
Doxil, used for breast cancer treatment in the USA, is lipo-
somally encapsulated doxorubicin, and SP1049C, which is 
currently in phase III clinical trials, is doxorubicin loaded 
into micelles [3,4]. Furthermore, both NP have surfaces that 
can be modified with polymers or targeting molecules to 
further enhance their functionality.  
Inorganic NP offer functions associated with their elec-
tromagnetic or photodynamic properties. For example, hol-
low gold NP can absorb specific wavelengths of light. In 
particular, they can be engineered to absorb light within the 
near infrared (NIR) spectrum. NIR light is known to pene-
trate deeper into biological tissue without causing ionizing 
damage. NIR-absorbing hollow gold NP that have been 
targeted to or injected into a tumor will heat up and destroy 
tumor cells if an NIR laser is applied to the tumor in a pro-
cess known as “photothermal ablation” [5]. NP composed 
of gadolinium are used aspowerful contrast agents provid-
ing signals thousands of times greater than background tis-
sue for magnetic resonance imaging (MRI) [6]. Silicon and 
silica particles have spurred interest in the nanotechnology 
field due to their versatile and flexible fabrication protocols 
capable of producing consistent NP with well-controlled 
sizes and shapes. Both materials can be porosified at the 
nanoscale allowing the loading of drugs, and their surfaces 
can be reacted with many different chemical moieties. In 
particular, the surface can be modified with targeting moie-
ties via bioconjugation techniques in order to tailor the in-
teraction with different types of cells and tissues [7]. Addi-
tionally, the highly porous matrices of these two materials 
serve as potential reservoirs for therapeutics and contrast 
agents to effectively operate as a carrier for these substances 
[8,9]. The most typical functions associated with NP in the 
biomedical arena are listed in Table 1. This is not to be con-
sidered a complete survey, as an exhaustive discussion of all 
NP would be out of the scope of this review and has been 
previously published [1,10–13]. The main limitations of NP 
such as the lack of selective targeting, bioavailability, and 
toxicity have fostered the development of delivery systems 
based on multifunctional NP. To overcome these obstacles, 
the physicochemical properties of NP such as size, shape,  
Table 1  Summary of nanoparticle types being developed for medical applicationsa) 
Nanoparticle function Subfunctions Types of nanoparticles General medical application References 







Deliver drugs to toxic or pathologic cells [14,15] 








Translocate particles within the body to a  
specific site 
[14,16] 
Triggered release pH responsive 
Thermoresponsive 
Electroresponsive 




Control the release of a drug or action of  
a nanoparticle in a spatiotemporal manner 
[17,18] 
Thermal ablation Photothermal ablation 
 
Gold nanoshells 
Super-paramagnetic iron  
oxide NP 
Heat up cells or tissue near NP sites [19,20] 




Super-paramagnetic iron  
oxide NP 
Enhance radiological studies [21,22] 
Magnetism Localized heating 
Particle accumulation 
Super-paramagnetic iron  
oxide NP 
Control particles via magnetic fields  
outside the body 
[23,24] 
a) General nanoparticle types are categorized by function and subfunction to deseribe their application towards areas of applied nanomedicine. 
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composition and surface properties are currently being in-
vestigated in greater detail. 
2  Obstacles in nanomedicine 
Due to the many obstacles the body provides, interest has 
shifted to engineer a delivery system with multifunctional 
aspects. In the past, some receptors were originally thought 
to provide specific targeting due to their high expression on 
cancer cells [25]; however, when these receptors were con-
jugated with NP, they exhibited unfavorable side effects. 
Furthermore, it is important to note that depending on the 
route of administration, NP will come into contact with 
various bio-barriers. The physicochemical properties (e.g. 
size, shape, and chemical composition) of functionalized 
NP determine the success in overcoming these barriers [26, 
27]—further success can be determined based on the NP 
ability to protect the cargo from degradation. The next pos-
sible issue may be in the toxicity of the NP itself once it 
reaches the target site and releases its payload. Ideally, the 
NP should be degraded or secreted without producing any 
adverse effects. Unfortunately, this is not always the case 
and while no clinically relevant toxicity has been reported, 
it is too soon to classify NP as completely inert [28–30].  
3  Advancing the hierarchy of nanocarriers 
The aforementioned difficulties encountered with NP, cou-
pled with their limited therapeutic success in the clinic, 
prompted the nanotechnology community to develop novel 
classes of NP. Previously, we have proposed that the organ-
ization of investigated nanocarriers, or nanovectors, can be 
effectively categorized into three generations or sub-cate- 
gories based on their purpose and intended function [31−34] 
(Figure 1). First generation carriers are composed of the 
base NP formulation (e.g. liposomes, micelles, gold, etc.) 
encompassing the agent (e.g. chemotherapeutics, siRNA, 
DNA, etc.). These first generation nanocarriers were the 
first NP developed and were approved for clinical use more 
than 15 years ago (e.g. liposomes). As described earlier, 
they passively accumulate at target lesions due to microen-
vironment abnormalities (e.g. fenestrations in the vessel 
walls of tumors). Second-generation nanocarriers advanced 
the field by incorporating new functions capable of either 
shielding or targeting first generation nanocarriers to spe-
cific markers found to be overexpressed in the target of 
choice. These second generation carriers accomplished this 
by attaching a variety of bio-recognition modalities and 
demonstrated efficient targeting of tissue abnormalities in 
vitro, as discussed earlier. Although these carriers have 
shown promise in animal experiments, they have struggled 
to achieve clinical efficacy and none to date have achieved 
approval from the US Food and Drug Administration. Re-
cently, novel classes of nanocarriers have emerged that ad-
vance the field by embedding unconventional sophistication 
into their development. These third generation nanocarriers 
(TGN) provide a paradigm shift in conventional thought and 
decouple the multiplicity of tasks required for nanocarriers 
to navigate intravascular delivery. They provide an elegant 
and sequential solution to address the common biological 
barriers (e.g. MPS, endothelial, etc.) encountered resulting 
in a significant improvement in tumor accumulation. Alt-
hough they are few in number, TGN are currently under 
investigation for their immense potential to drastically im-
prove the clinical efficacy while maintaining an overall low 
therapeutic index, a hallmark of the currently available NP 
therapeutics. The remainder of this review will be dedicated 
to highlighting these TGN (Table 2), with a major influence 
placed on cancer therapy (i.e. treatment and imaging) and 
introducing our lab’s interpretation and solution, the Multi-
stage Silicon Nanocarriers. 
4  Third generation nanocarriers 
The nanotechnology community is constantly redefining 
nanocarriers aimed at executing several functions to obtain 




Figure 1  Hierarchy of nanocarriers. (a) First-generation nanocarriers’ (e.g. liposomes, micelles) primary role is to enclose therapeutic or diagnostic agents 
and then localize in tumors by the EPR effect. (b) Second-generation nanocarriers improved by incorporating further modifications allowing for specific 
targeting via antibodies or other recognition biomolecules or “stealthing” from MPS sequestration. (c) Third-generation nanocarriers advanced the field by 
creating platforms capable of incorporating and preforming multiple complex functions due to their nanoscale features (e.g. multistage silicon nanocarriers 
ability to deploy multiple waves of nanoparticles). Reproduced with permission, © Wiley-VCH Verlay GmbH & Co. KGA [33].  
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Table 2  Comparison of first, second, and third generation vectorsa) 
Generation Nanocarrier Size (nm) Obstacles Advantages 
First 
Liposome 50–200 Deliver a payload to 
target lesions 
Passively circulate and accumulate due to biological 
abnormalities Micelles 10–100 
Gold 2–200 
Second 
Bio-recognition modalities  
attached to first generation  
nanocarriers 
 Inability to accumu-
late at target tissue 
Attaching bio-recognition modalities allows for  
exploitation of target tissue abnormalities 
Third 






Biological barriers  
impede successful  
delivery of payload 
Navigate blood stream  
Recognize diseased vasculature 
Retain and release payload 
Ability to elicit a signaling or biological cascade,  
resulting in receptors able to attract agents 
Nanoshells 100–200 nm Absorb light in NIR allowing for external activation 
Absorb or scatter light enabling several imaging  
applications 
Nanorods Length  
15–70 nm 




Nanocell 180–200 nm Temporal release of payload 
Protocell 100–150 nm Stability to lipid membrane and increase in delivery agent 
a) Different generations were compared using size, intended obstacles they could accomplish, and advantages. 
 
to tackle the heterogeneous nature of tumors, but can poten-
tially be applied to several disorders based on the versatility 
of the systems. TGN contain a complex nano-sized feature 
that imparts an innovative trait allowing for an unprece-
dented function not available in second-generation carriers. 
Examples of these carriers include gold-containing NP, 
which can use tunable optical properties to absorb light in 
the NIR, thus allowing for external activation in the clinic 
due to the low absorption of biologics (i.e. water and hemo-
globin) within this region [35] and integrate other properties 
based on gold’s versatility. Solid gold NP display surface 
plasmon resonance throughout the visible spectrum red 
shifting with increases in size (spherical) or aspect ratio 
(rods) [36]. However NIR absorption is not the case for all 
gold NP, for example, spherical gold NP display absorption 
spectra with minor redshifts as the diameter increases, with 
peak absorbance ranging from 520 to 600 nm [36]. On the 
other hand, gold nanorod’s (Figure 2(a)) resonance fluctu-
ates based on their aspect ratio (length/width), and with in-
creases to this ratio, their spectra significantly shifts well 
into the NIR region, with peak absorbance ranging from 600 
to 900 nm [36]. Another gold-containing NP example is 
nanoshells (Figure 2(a)). Nanoshells typically range from 
100 to 200 nm in diameter, and are composed of a dielectric 
core enclosed by a thin metallic (typically gold) layer with 
tunable properties [37,38]. The archetypical nanoshell in-
volves a silica core (110–120 nm diameter) with a 10 nm 
layer of gold resulting in peak surface plasmon resonance at 
800 nm, capable of providing photothermal therapy using 
NIR excitation [39–41]. As with gold spheres and rods, a 
similar phenomenon was discovered with gold nanoshells 
where decreases in the thickness of the outer gold layer 
would significantly redshift the absorption spectra well into 
the NIR region [42]. Moreover, one can vary the core/shell 
ratio of nanoshells to affect their ability to absorb or scatter 
light, thus enabling their use not only for photothermal ap-
plications but also for several imaging applications [41–43]. 
In addition, fluorescent enhancement of NIR dyes without 
alteration of the photothermal properties can be achieved by 
using a silica spacer on nanoshells [44,45] and with human 
serum albumin for shells and rods [46] thus enabling signif-
icant increases in fluorescent intensity due to nanoscale ef-
fects. Furthermore, dual magnetic resonance and optical 
imaging enhancement was also achieved using a silica layer 
by doping it with iron oxide and NIR dye on a nanoshell, 
resulting in a platform capable of targeting (via monoclonal 
antibody), photothermal activation, and imaging [47]. Re-
cently, the labs of Zhang and Li [5,48–51] have demon-
strated that hollow gold nanospheres retain the photother-
mal properties of nanoshells and have used them for cancer 
applications and have incorporated them with chemothera-
peutic agents such as doxorubicin. Another gold-related 
approach incorporates the intrinsic properties of spherical 
gold NP and bacteriophages to create self-assembled net-
works of gold NP-embedded phages (Au-phage) with 
unique properties that emerge from this synergism [52]. 
These Au-phages (Figure 2(b)) spontaneously organize and 
maintain the biological properties of phages, including their 
ability to target cells, coupled with the unique properties of 
gold NP. Moreover, they can act as enhanced and superior 
reporters for fluorescence and dark field microscopy and 
provide a redshift in gold NP absorbance, allowing for NIR 
absorption for in vivo photothermal therapy [52,53]. Gold 
nanoshells, rods, and hollow spheresare considered TGN 
based on their nano-sized features that enable novel proper-
ties to emerge that will facilitate success in the clinic at-
tributed to their ability to modulate NIR absorbance. Spher-
ical gold NP alone are not considered TGN due to their 
ability to only absorb light shorter than 600 nm, however 
when integrated with phage technology novel properties   
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Figure 2  Third-generation nanocarrier platforms. (a) Gold nanoshells and rods display unique photothermal properties and can enhance fluorescent and 
magnetic properties when coupled to their surface. (b) Au-phage networks are the result of the unique synergism yielded upon the incorporation of gold 
nanoparticles with bacteriophages, schematic is shown here displaying the effect of charge. Adapted from [52] and reproduced by permission from Jonathan 
O. Martinez, Methods in Bioengineering: Nanoscale Bioengineering and Nanomedicine, Norwood, MA: Artech House, Inc., 2009. © 2009 by Artech House, 
Inc. (c) Nanocells are comprised of two compartments (nucleus and envelope) which allows for the temporal release of agents enabling time-dependent 
delivery of therapeutics, adapted from [54]. (d) Protocells are nanoporous silica cores supported by a lipid bilayer. The porous core allows for the incorpora-
tion of a diverse array of cargoes, while the lipid bilayer enables for further conjugation of targeting and fusogenic peptides yielding an agent capable of 
providing a “one nanoparticle, one kill”. Reproduced with permission from NPG [55]. (e) Embedded nanoparticles enable the concentrated delivery of 
smaller nanoparticles deep within the tumor site by taking advantage of the responsive nature of larger nanoparticles to tumor microenvironment cues (e.g. 
Gelatin & MMP-2). Reproduced from [60] with permission from National Academy of Sciences, USA. (f) Communicating nanoparticles benefit from the 
amplification of signals created through biological cascades resulting in significant increases in nanoparticle tumor accumulation. Using the increases in 
factors involved in the coagulation cascade, via the heating of gold nanorods, one could effectively increase the accumulation of targeted therapeutic and 
diagnostic agents. Reproduced with permission from NPG [61].  
emerge including the ability to home to targets and     
enhanced NIR heating all in a single, self-assembled pack-
age. Furthermore, these NP can be decorated with bio-    
recognition moieties or polymers as with second generation 
carriers.  
TGN could also be synthesized or fabricated to have 
cell-mimicking coatings or properties. These inherited 
properties allow these nanocarriers an advanced degree of 
integration into the hosts system by mimicking cells com-
monly encountered during targeting. One such system was 
devised to co-deliver two anti-cancer drugs imparting dis-
tinct release profiles to each drug [54]. This system was 
composed of a central polymer-based NP containing drug A 
encircled by a PEGylated-lipid compartment, which cap-
tured and retained drug B until the outer lipid layer was 
completely compromised. These “nanocells” (Figure 2(c)) 
allowed for the temporal release of the entrapped drugs, and 
the proof-of-principle was demonstrated by trapping the 
anti-angiogenesis agent combretastatin in the envelope/lipid 
capsule of the nanocell. A doxorubicin-PLGA conjugate 
was used to form the nucleus and concentrate doxorubicin 
within the core of nanocells. Sengupta et al. [54] created 
180–200 nm carriers and illustrated that by using this novel 
approach a synergistic combination could be achieved. Spe-
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cifically, the anti-angiogenesis agent lead to the collapse of 
tumor associated vessels resulting in the effective entrap-
ment of nuclear NP within the tumor where they could pro-
vide a steady release of doxorubicin, killing the remainder 
of the cells. A similar, yet different approach uses a na-
noporous silica NP nucleus supported by a lipid bilayer 
membrane (i.e. liposomes) resulting in a carrier of 100–150 
nm. Moreover, the lipid bilayer membrane can incorporate 
further functionalization (for targeting, endosomal disrup-
tion, and shielding) while the silica core absorbs and retains 
multiple combinations of agents allowing for potential drug 
cocktails. Ashley et al. [55] demonstrated that the silica core 
of these “protocells” (Figure 2(d)) imparted significant sta-
bility to the lipid membranes, displaying a 100-fold increase 
in targeting cells, and 1000-fold increase in the delivery of 
agents (chemotherapeutics, siRNA, QD) when compared 
with clinically prepared liposomes [56]. Furthermore, pro-
tocells impressively demonstrated an unprecedented 10000- 
fold increased affinity for human hepatocellular carcinoma. 
This enhancement was so potent that when carrying a cock-
tail of chemotherapeutics, a single protocell was capable of 
killing a single cancerous cell. An alternative approach is to 
fabricate carriers that mimic red blood cells (RBC) [57–59], 
a major constituent of blood. Doshi et al. [57] synthesized 
RBC-like particles by using a PLGA template, followed by 
layer-by-layer addition and protein cross-linking yielding 
carriers capable of carrying oxygen, flowing through capil-
laries, and encapsulate a variety of agents, including NP. In 
a related study, Merkel et al. [58] observed that carriers de-
signed to match the elastic modulus of RBC were found to 
extend their circulation time in blood. On the other hand, 
rather than synthesizing carriers of similar shape and size, 
Hu et al. [59] imparted RBC-like properties by camouflag-
ing the surface of PLGA NP with natural erythrocyte mem-
branes. This RBC-coated NP demonstrated superior blood 
circulation and maintained the associated proteins of natural 
RBC. The biomimetic strategies discussed provide powerful 
solutions to conventional second generation carriers by ena-
bling enhanced targeting, co-delivery of drug cocktails, and 
improved blood circulation. 
Other TGN function by relying on the synergism and 
cooperation of multiple NP resulting in superior enhance-
ment in delivery and therapy of agents [60,61]. One such 
example of NP synergism was proposed by developing a 
system where a tumor “sensing” (i.e. reactive to cues found 
within tumor microenvironment) NP would contain several 
smaller NP within its core (Figure 2(e)). The rationale be-
hind this approach was to retain the properties of 100 nm 
NP (e.g. passive targeting, long circulation) and upon 
reaching the tumor, the larger NP would degrade forcing the 
release of smaller NP to deeply penetrate the dense matrix 
of tumors typically hindered by larger NP. Wong et al. [60] 
demonstrated a proof-of-principle using 100 nm gelatin NP 
containing 10 nm QD which when triggered by proteases, 
(e.g. matrix metalloproteinases) would cause degradation or 
shrinkage of the larger gelatin particles allowing the QD to 
diffuse deeper into tumor tissue. This NP system conserved 
the long circulation time and tumor penetration (via EPR 
effect) assets pertaining to 100–200 nm NP while also cou-
pling the favorable attributes of smaller NP to deliver agents 
with significantly improved tumor penetration. Yet another 
strategy relies on using NP to elicit a signaling or biological 
cascade, which in turn creates an abundance of receptors 
that can attract agents (Figure 2(f)). von Maltzahn et al. [61] 
proved this strategy by taking advantage of the coagulation 
cascade and constructed systems to intensify disease target-
ing. The designs of these systems relied on the synergism of 
“signaling” (NP or engineered proteins) and “receiving” 
(therapeutic or diagnostic) modules to activate the coagula-
tion cascade, thus relaying the location and attracting the 
circulating clot-targeted NP. Signaling components ex-
plored here include gold nanorods and RGD-targeted hu-
man tissue factor which elicited the activation of the coagu-
lation cascade by photothermal disruption of tumor vessels 
and by binding to αvβ3 in tumor blood vessels, respectfully. 
This “signaling” activation enabled communication to re-
cruit and amplify receiving components to the site of the 
signaling carriers. The investigators confirmed the ampli-
fied recruitment of diagnostic (iron oxide nanoworms) and 
therapeutic (doxorubicin-loaded liposomes) receiving com-
ponents through the tethering of active coagulation trans- 
glutaminase FXIII or targeted fibrin. This in vivo commu-
nication resulted in autonomous operation, increasing the 
targeting 40-fold over non-communicating NP. The dis-
cussed strategies established novel methods in the delivery 
and recruitment of NP to diseased sites, specifically to tu-
mors, and provided simple methods to increase the delivery 
while reducing the potent toxicity of chemotherapeutics.  
5  Multistage silicon nanocarriers 
Our laboratory envisioned, designed, and engineered Multi-
stage Silicon Nanocarriers (MSN), a unique and innovative 
example of TGN. Our strategy was to decouple the multi-
plicity of tasks required to a single NP and distribute them 
onto multiple stages. According to this approach, the first 
stage carrier is responsible for the navigation through the 
bloodstream, the avoidance of MPS, the recognition of the 
diseased vasculature, and the retention and release of the 
embedded second-stage particles [62,63]. The second-stage 
particles are NP able to extravasate through vessels’ fenes-
trations and diffuse in the tumor parenchyma, thus concen-
trating diagnostic and therapeutic agents within the target 
microenvironment. In addition, these second stage NP can 
be functionalized with cancer specific ligands allowing for 
cell-specific targeting within the tumor (Figure 3(a)–(c)).  
Obtaining clinical success requires carriers to be de-
signed such that they meet a stringent set of criteria. A crit-
ical aspect of the MSN design is the appropriate material for   
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Figure 3  Schematic and SEM micrographs describing the process and shape of multistage silicon nanocarriers. (a) MSN is initially loaded with se-
cond-stage NP into the pores of the silicon nanocarriers. Upon systemic administration, the rational design of MSN allows them to travel within the blood- 
stream, avoid MPS sequestration, and preferentially drift towards the target’s endothelium and firmly adhere. Once docked, MSN can release their cargo (i.e. 
second stage NP) that will infiltrate into the target’s microenvironment where they can specifically target diseased cells and fulfill their final objective. (b) 
Overall view of a view MSN illustrating the uniform size and shape within each fabrication batch. (c) Magnified image of the nano-sized pores of MSN, 
which can serve to accommodate a variety of NP. Reproduced with permission from [62].  
the first stage. This material must be biocompatible, biode-
gradable, versatile surface for chemical modification, and 
flexible fabrication schemes enabling defined control over 
shape and size. With this in mind, we chose porous silicon 
as the material of choice [64–67], whose porosity would be 
able to accommodate a broad range of NP. By using ad-
vanced modeling of the blood rheology, margination (i.e. 
the propensity to drift towards vessel walls) and flow dy-
namics, vascular targeting, vessel permeability, and endo-
thelial adhesion and internalization, we rationally designed 
MSN to contain the optimal attributes for optimal intravas-
cular delivery [68–74]. We demonstrated the ability to fab-
ricate carriers in several shapes (e.g. hemispherical, dis-
coidal, and cylindrical), sizes (400–3000 nm) and pore sizes 
(3–150 nm) yielding monodispersed particles [9] (Figure 
3(d),(e)) capable of retaining a variety of NP (Figure 4) (e.g. 
QD [62], carbon nanotubes [62,75], fullerenes [75], 
nanoliposomes [76], iron-oxide [77,78], and gold [79,80]). 
Furthermore, the in vitro and in vivo degradation of MSN 
was verified and demonstrated no significant adverse reac-
tions [81]. Additionally, MSN were found to degrade in 
various physiological environments (PBS, serum, media, 
and blood) into orthosilicic acid and their degradation rate 
could be tailored through PEGylation [82,83]. Investigating 
the in vitro interactions of MSN with endothelial and mac-
rophage cells illustrated no effect on their proliferation, cell 
cycle, or apoptosis, and failed to produce an increase in the 
expression of several inflammatory cytokines [79,82,83]. 
Similar results were revealed in vivo when investigating the 
effect of acute and sub-chronic administration of MSN, 
which demonstrated within the span of a month no signifi-
cant release of biochemical markers or cytokines in the 
blood plasma of exposed mice [84]. Furthermore, the ability 
of MSN to marginate and localize to the diseased endothe-
lium is highly dependent on its shape and size, and has been 
extensively studied within our group [69–71]. We conclud-
ed that when used for intravascular delivery, dis-
coidal-shaped MSN yielded the highest concentration of 
silicon in tumors, all the while reducing accumulation in the 
liver [85]. Expanding on these results, our group examined 
the effect of size on the distribution of discoidal (or “plate-
loid”) MSN by coupling intravital microscopy with ele-
mental analysis. van de Ven et al. [86] determined that 1000 
nm MSN preferentially accumulated in tumors at higher 
numbers and concentration than 600 and 1800 nm carriers. 
Furthermore, our group reported an unprecedented concen-
tration of MSN to rapidly (less than 1 h) emerge at tumor 
sites at almost 10% of the injected dose per gram of organ 
for RGD-targeted carriers. In addition, Mann et al. [87] dis-
played enhanced vascular targeting of MSN to the bone 
marrow using an E-selectin thioaptamer covalently linked to 
its surface and retained the ability to load NP.  
The loading and release of NP relies on several condi-
tions, as well as synergism between the dimensions, charge   
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Figure 4  Loading and release of nanoparticles from MSN. (a)–(c) Loading of NP (liposomes, quantum dots) into MSN. (a), (b) Flow cytometry of loading 
comparing the fluorescence of MSN, either unloaded (black) or with NP-loaded ((a) green, liposomes; (c) red, quantum dots). (c) Fluorescent image of MSN 
containing FITC labeled nanoliposomes. (d) Release profiles of quantum dots from oxidized (blue) and APTES modified (red) MSN.  
and concentration of the payload and MSN [31,62]. Using a 
1000 nm MSN as an example, we calculated that each MSN 
would be able to accommodate 3.8×105 NP (assuming a 10 
nm diameter). Experimental results, using 10 nm iron oxide 
NP, revealed that we could effectively load 0.3 pg of iron 
(~1×105 NP) per MSN [31]. In addition, the surface of MSN 
represents a suitable platform for covalent and electrostatic 
attachment of fluorescent dyes, radioactive molecules, pro-
teins, polymers, and other NP [83,88,89]. For example, 
bacteriophage networks (phages + gold NP) have been at-
tached to MSN based on electrostatic interactions producing 
multifunctional nanoassemblies [31]. We have also demon-
strated the controlled and stable release of biomolecules 
through PLGA/MSN complexes and agarose surface coat-
ings thus enabling intermediate release profiles of the em-
bedded biomolecules (Figure 5) [88,89]. In addition, NP 
retention and release could be controlled by conjugating 
silanes to the surface of MSN that imparted a delayed re-
lease when compared to uncoated carriers and was capable 
of retaining the payload in vivo [77].  
Furthermore upon loading with NP, MSN exhibit en-
hanced properties capable of providing novel and greatly 
improved imaging and therapeutic agents. Ananta et al. [75] 
illustrated that by loading MSN with gadolinium-based 
contrast agents, incorporated within carbon NP, would dra-
matically alter the longitudinal relaxivity for MRI resulting 
in an 40-fold increase over clinically used agents. Moreover, 
loading MSN with iron oxide NP resulted in constructs with 
shorter relaxation times, providing increased negative con-
trast for T2 weighted MRI [77]. Enhanced efficacy using 
MSN was achieved by delivering nanoliposomes containing 
siRNA to orthotropic models of ovarian cancer. After a sin-
gle administration of siRNA loaded MSN, prolonged gene 
silencing and decreased tumor burden was observed over 
three weeks [81]. On the other hand, to achieve a similar 
effect with nanoliposomes alone required multiple doses a 
week. The proposed mechanism for this sustained delivery 
relies on the slow degradation of MSN in vivo, and thus this 
approach could be applicable for the long-term release of 
several embedded NP resulting in less doses needed to treat 
tumors. Recently, Shen et al. [80] discovered that upon 
loading MSN with NIR responsive NP (hollow gold NP), a 
significant increase in heat generation and killing of breast 
tumor cells (regardless of genetic background) was ob-
served. This cooperative thermal therapy packaging be-
tween MSN and hollow gold NP revealed benefits that red 
shifted the absorption enabling deeper penetration within 
tissues. Furthermore, the nanoscale organization within 
MSN permitted more efficient energy-to-heat conversion 
resulting in a strengthened therapeutic response. Hence, by   
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Figure 5  Coating and delayed release of biomolecules from MSN. (a)–(d) SEM micrographs demonstrating the coating of MSN with agarose ((a),(b)) and 
gelatin ((c),(d)) at the single particle scale ((a),(c)) and pore scale ((b),(d)). (e) Release profiles of BSA-FITC from uncoated (black), agarose (blue), and 
gelatin (red) coated MSN. The coating of MSN yielded a delay in the release of BSA enabling kinetics not possible without a coating.  
loading NP into MSN novel features emerged resulting in 
an unprecedented amplification in function. 
6  Conclusion 
In conclusion, multifunctional nanocarriers are the product 
of cumulative research in the nanotechnology field applied 
to modern medicines. Third generation nanocarriers repre-
sent the latest technology designed to address multiple clin-
ical demands while simultaneously addressing limitations of 
conventional nanoparticles. Multifunctional nanocarriers 
represent the products of an ever-growing array of “nano” 
building blocks; the most relevant to our work corresponds 
to the Multistage Silicon Nanocarriers. This has been seen 
with the delivery of both contrast agents and bioactive drugs 
for the diagnosis and treatment within a contained system. 
However, issues still remain with regard to the assessment 
and verification of in vivo cytotoxicity, biocompatibility 
testing, and clinical approvals. These remain paramount 
areas of focus in developing next generation nanocarriers 
that have been designed specifically to address human dis-
eases. Future formulations can be expected to incorporate 
newly designed nanomaterials that leverage existing con-
structs such as protocells and multistage particles to en-
hance the potential attributes of future nano-based delivery 
platforms.  
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